Abemaciclib · Verzenio

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Glioma · Phase 2 · investigational in the US

Also approved (2)
EU
  • Early Breast Cancer Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1). In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or Metastatic Breast Cancer Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal...
Product first approved 2018EMA
JP
  • Treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)- negative inoperable or recurrent breast cancer
Product first approved 2018PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (24)
Breast Cancer
NCT05952557 · AstraZeneca
2023-10-05 – 2037-05-06 · Breast Cancer, Early Breast Cancer
What this study did
NCT07190443 · Japanese Foundation for Cancer Research
2025-02-07 – 2035-02-06 · Breast Cancer, Locoregional Recurrence, Abemaciclib, Endocrine Therapy
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
NCT04565054 · Women's Cancer Study Group GmbH
2020-09-02 – 2029-07 · Breast Cancer Female
What this study did
NCT06341621 · Fudan University
2024-04-02 – 2029-01-01 · Breast Cancer
What this study did
NCT06152471 · Henrik Lindman
2023-06-07 – 2025-03-31 · Early-stage Breast Cancer, Diarrhea, Adverse Drug Event
What this study did
NCT04752332 · Eli Lilly and Company
2021-05-10 – 2024-06-26 · Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04158362 · UNICANCER
2020-06-11 – 2032-06 · Cancer Metastatic
What this study did
NCT04584853 · Institute of Cancer Research, United Kingdom
2020-12-23 – 2030-10 · Breast Cancer Female
What this study did
NCT04862663 · AstraZeneca
2021-05-10 – 2029-08-14 · Locally Advanced (Inoperable) or Metastatic Breast Cancer
What this study did
NCT06065748 · Hoffmann-La Roche
2023-12-11 – 2029-02-12 · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
What this study did
NCT04964934 · AstraZeneca
2021-06-30 – 2028-09-01 · ER-Positive HER2-Negative Breast Cancer
What this study did
NCT02763566 · Eli Lilly and Company
2016-12-05 – 2028-03 · Breast Cancer
What this study did
NCT04975308 · Eli Lilly and Company
2021-10-04 – 2027-08 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT05065411 · Veru Inc.
2022-04-11 – 2024-01-09 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT04967521 · Sarcoma Alliance for Research through Collaboration
2021-11-11 – 2027-12 · Advanced Dedifferentiated Liposarcoma
What this study did
NCT05288166 · Eli Lilly and Company
2022-04-14 – 2027-10 · Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03706365 · Eli Lilly and Company
2018-11-26 – 2026-12 · Prostate Cancer
What this study did
Phase 2 (94)
Breast Cancer
NCT04293393 · Spanish Breast Cancer Research Group
2020-10-02 – 2033-02-28 · Early Breast Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07292207 · Nagoya City University
2026-01-10 – 2031-08-31 · ctDNA Monitoring, Breast Cancer
What this study did
NCT07410559 · Fudan University
2026-07-01 – 2031-07-01 · Breast Cancer
What this study did
NCT07340541 · UNC Lineberger Comprehensive Cancer Center
2026-02-16 – 2031-06-02 · Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
What this study did
NCT07191717 · Jonsson Comprehensive Cancer Center
2026-05-18 – 2031-04-30 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma, Localized Estrogen Receptor-Positive Breast Carcinoma, Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
What this study did
NCT07428018 · Mario Negri Institute for Pharmacological Research
2026-04-30 – 2029-04-30 · Breast Cancer, HER2 + Breast Cancer, HR Positive, Neoadjuvant Therapy
What this study did
NCT06365788 · Universitaire Ziekenhuizen KU Leuven
2024-04-08 – 2028-12 · Triple Negative Breast Neoplasms
What this study did
NCT04614194 · University of Texas Southwestern Medical Center
2021-04-15 – 2028-04-15 · Breast Cancer
What this study did
NCT07935317 · Eli Lilly and Company
2026-12 – 2028-01 · Breast Neoplasms
What this study did
NCT06259929 · Fondazione Oncotech
2025-01-27 – 2027-04-01 · Breast Cancer
What this study did
NCT06001762 · Dana-Farber Cancer Institute
2023-10-05 – 2027-01-01 · Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
What this study did
NCT03979508 · Mayo Clinic
2020-01-10 – 2024-12-26 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT04351230 · Academic and Community Cancer Research United
2020-11-11 – 2022-02-16 · Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT04305236 · University of California, Irvine
2020-07-23 – 2022-02-16 · Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma
What this study did
NCT03130439 · Dana-Farber Cancer Institute
2017-05-26 – 2022-01-30 · Breast Cancer
What this study did
NCT02441946 · Eli Lilly and Company
2015-08 – 2018-02-12 · Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
What this study did
NCT02831530 · Gustave Roussy, Cancer Campus, Grand Paris
2016-03-16 – 2018-02-02 · Breast Cancer
What this study did
Glioma
HR+/HER2- Metastatic Breast Cancer
NCT05501704 · Jose Pablo Leone
2023-10-11 – 2036-04-01 · Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
What this study did
NCT05524584 · University of California, Irvine
2022-08-31 – 2031-12-31 · Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05933395 · Dartmouth-Hitchcock Medical Center
2024-09-23 – 2031-10 · Advanced Breast Cancer
What this study did
NCT07605728 · Leeuwenhoek Laboratories Co. Ltd.
2026-05-15 – 2029-12-31 · Breast Cancer, Chemotherapy-induced Diarrhea
What this study did
NCT06062498 · Northwestern University
2023-09-29 – 2029-07-01 · Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
What this study did
NCT07112053 · University of Washington
2025-11-17 – 2028-12-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT04523857 · Abramson Cancer Center at Penn Medicine
2021-11-01 – 2028-12 · Breast Cancer
What this study did
NCT06207734 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2024-01-17 – 2028-07-10 · Breast Cancer
What this study did
NCT05708235 · MedSIR
2024-04-01 – 2028-06-30 · Breast Cancer
What this study did
NCT06179303 · University of Washington
2024-07-22 – 2028-06-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT05872204 · Universitaire Ziekenhuizen KU Leuven
2023-11-30 – 2028-01 · Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
What this study did
NCT05305924 · The Methodist Hospital Research Institute
2021-02-25 – 2027-12-01 · ER-Positive Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT04305834 · City of Hope Medical Center
2020-06-05 – 2027-05-21 · Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT02747004 · Eli Lilly and Company
2016-09-14 – 2026-09-09 · Metastatic Breast Cancer
What this study did
NCT06561022 · Fudan University
2024-08-21 – 2026-06-30 · Breast Cancer
What this study did
NCT06630325 · OHSU Knight Cancer Institute
2025-06-24 – 2026-03-11 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
What this study did
NCT04603183 · MedSIR
2021-06-02 – 2025-06-30 · Breast Cancer Metastatic
What this study did
NCT04352777 · Duke University
2020-09-14 – 2025-06-25 · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Hormone Receptor Positive Tumor
What this study did
NCT04432454 · Sermonix Pharmaceuticals Inc.
2020-09-29 – 2025-01-28 · Metastatic Breast Cancer
What this study did
NCT04227327 · University of Milano Bicocca
2020-01-07 – 2024-07-25 · Advanced Breast Cancer
What this study did
NCT02675231 · Eli Lilly and Company
2016-05-23 – 2023-11-09 · Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
What this study did
NCT04256941 · M.D. Anderson Cancer Center
2019-05-31 – 2023-09-22 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03703466 · Eli Lilly and Company
2018-11-28 – 2023-03-09 · Metastatic Breast Cancer
What this study did
NCT02308020 · Eli Lilly and Company
2015-04-20 – 2019-11-08 · Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
What this study did
Other / comorbidity
NCT05159245 · Helsinki University Central Hospital
2021-12-10 – 2032-11-25 · Advanced Cancer, Solid Tumor, Haematological Malignancy
What this study did
NCT03675893 · Dana-Farber Cancer Institute
2018-12-24 – 2031-08-01 · Endometrial Cancer
What this study did
NCT05940493 · Nader Sanai
2025-03-24 – 2030-09 · Meningioma
What this study did
NCT07832227 · Dana-Farber Cancer Institute
2026-12-01 – 2029-08-01 · Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
What this study did
Phase 1/2 (35)
Glioma
NCT06810544 · Tango Therapeutics, Inc.
2025-03-24 – 2027-09-30 · Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT05867251 · Avenzo Therapeutics, Inc.
2023-08-30 – 2030-01-31 · Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT04802759 · Hoffmann-La Roche
2021-06-22 – 2029-05-30 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
What this study did
NCT05386108 · Stemline Therapeutics, Inc.
2022-08-31 – 2029-02 · Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
What this study did
NCT05608252 · Adrienne G. Waks
2023-02-23 – 2028-12-31 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
What this study did
NCT05563220 · Stemline Therapeutics, Inc.
2023-01-24 – 2028-12-28 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT07002177 · Forward Pharmaceuticals Co., Ltd.
2025-06-01 – 2028-11-01 · Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
What this study did
NCT05095207 · Icahn School of Medicine at Mount Sinai
2021-09-20 – 2028-06 · Breast Cancer, Metastasis
What this study did
NCT05573126 · Ellipses Pharma
2023-01-11 – 2028-02 · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04923542 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-30 – 2027-12 · Brain Metastases, HR+ Metastatic Breast Cancer
What this study did
NCT05735080 · Incyclix Bio
2023-03-28 – 2027-09 · Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
What this study did
NCT06188520 · AstraZeneca
2023-12-05 – 2027-06-30 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
What this study did
NCT05464173 · Biyun Wang, MD
2022-07-01 – 2025-05-01 · Breast Cancer
What this study did
NCT04791384 · Criterium, Inc.
2022-04-21 – 2024-09-17 · Breast Cancer
What this study did
Other / comorbidity
NCT04750928 · National Cancer Institute (NCI)
2021-11-29 – 2029-12-31 · Neurofibromatosis 1
What this study did
NCT04616183 · M.D. Anderson Cancer Center
2020-12-02 – 2028-12-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Unresectable Rectal Adenocarcinoma
What this study did
NCT05113537 · Vadim S Koshkin
2022-07-08 – 2028-12-31 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT05774899 · Michael J. Dennis, MD
2023-06-01 – 2028-06-01 · Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
What this study did
NCT04941274 · National Cancer Institute (NCI)
2021-09-29 – 2028-06-01 · Kaposi Sarcoma
What this study did
NCT04486352 · Alliance Foundation Trials, LLC.
2021-10-20 – 2027-10 · Endometrial Cancer
What this study did
NCT06594679 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2024-09-26 – 2027-09-18 · Ovarian Cancer
What this study did
NCT06835972 · Memorial Sloan Kettering Cancer Center
2025-02-14 – 2027-02 · Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
What this study did
NCT06498648 · National Cancer Institute (NCI)
2026-03-18 – 2027-01-31 · Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
What this study did
NCT04238819 · Eli Lilly and Company
2020-11-09 – 2025-08-19 · Relapsed Solid Tumor, Refractory Solid Tumor
What this study did
NCT04921904 · Baylor Research Institute
2021-06-11 – 2025-08-14 · Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04092673 · Effector Therapeutics
2019-10-25 – 2025-03-31 · Solid Tumor, Adult
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT04594005 · Yonsei University
2021-02-25 – 2024-08-10 · Tumors
What this study did
NCT04165031 · Eli Lilly and Company
2019-11-28 – 2020-10-30 · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT03655444 · Washington University School of Medicine
2019-05-29 – 2020-08-24 · Head and Neck Squamous Cell Carcinoma
What this study did
Phase 1 (60)
Breast Cancer
NCT04481113 · OHSU Knight Cancer Institute
2021-06-07 – 2025-06-20 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
What this study did
NCT04088032 · Alison Stopeck
2019-10-01 – 2020-12-31 · Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT03846583 · Dana-Farber Cancer Institute
2020-06-28 – 2020-09-22 · Breast Cancer
What this study did
Glioma
NCT05413304 · National Cancer Institute (NCI)
2023-04-07 – 2027-09-01 · Glioma
What this study did
NCT04391595 · Nader Sanai
2020-07-11 – 2025-09-03 · Glioblastoma, GBM, Glioma
What this study did
NCT02644460 · Emory University
2016-02 – 2023-10-10 · Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
What this study did
NCT04220892 · Jose Carrillo
2020-07-08 – 2020-07-08 · High Grade Glioma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06139107 · Mridula George, MD
2024-08-22 – 2032-09-30 · Breast Cancer
What this study did
NCT07905001 · Prelude Therapeutics Incorporated
2026-11-16 – 2029-10-31 · Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer, HR+/HER2- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06678269 · Memorial Sloan Kettering Cancer Center
2024-11-15 – 2028-11-30 · Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
What this study did
NCT04316169 · Medical College of Wisconsin
2021-10-21 – 2028-01 · Solid Tumor, Advanced Breast Cancer
What this study did
NCT04188548 · Eli Lilly and Company
2019-12-10 – 2027-12 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
What this study did
NCT03939897 · National Cancer Institute (NCI)
2020-06-17 – 2027-07-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
What this study did
NCT03616587 · AstraZeneca
2018-10-11 – 2027-06-24 · ER+ HER2- Advanced Breast Cancer
What this study did
NCT05372640 · National Cancer Institute (NCI)
2023-08-10 – 2027-06-07 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
What this study did
NCT05307705 · Eli Lilly and Company
2022-05-11 – 2026-12 · Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT02779751 · Eli Lilly and Company
2016-11-14 – 2026-12 · Non Small Cell Lung Cancer, Breast Cancer
What this study did
NCT06570031 · Ono Pharmaceutical Co., Ltd.
2021-11-09 – 2026-04-30 · Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT05189717 · Shandong Suncadia Medicine Co., Ltd.
2022-02-17 – 2025-07-31 · Metastatic or Local Advanced Breast Cancer of Patients
What this study did
NCT05759949 · Relay Therapeutics, Inc.
2023-03-29 – 2025-04-11 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
What this study did
NCT02791334 · Eli Lilly and Company
2016-06-29 – 2024-06-27 · Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
What this study did
NCT04514159 · Zeno Alpha Inc.
2020-11-12 – 2022-10-24 · Breast Cancer
What this study did
NCT01655225 · Eli Lilly and Company
2012-07-31 – 2022-02-02 · Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
What this study did
NCT04585724 · Emory University
2020-06-12 – 2021-09-13 · Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02784795 · Eli Lilly and Company
2016-11-04 – 2020-02-13 · Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
What this study did
Other / comorbidity
NCT06025747 · University of Washington
2025-03-19 – 2028-03-03 · Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
What this study did
NCT04633239 · National Cancer Institute (NCI)
2021-07-02 – 2027-05-01 · Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
What this study did
NCT03837821 · Weill Medical College of Cornell University
2019-02-05 – 2027-05 · Bladder Cancer
What this study did
NCT06654037 · National Cancer Institute (NCI)
2025-04-18 – 2027-04-01 · Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
What this study did
NCT06959979 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2024-11-25 – 2027-02-28 · Medulloblastoma, Childhood
What this study did
NCT05714072 · Memorial Sloan Kettering Cancer Center
2023-01-25 – 2027-01 · Myelofibrosis Due to and Following Polycythemia Vera
What this study did
NCT07818967 · Eli Lilly and Company
2026-09-02 – 2026-11 · Healthy Volunteers
What this study did
NCT05617885 · Praful Ravi, MB BCHir, MRCP
2023-08-09 – 2026-06-01 · Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
What this study did
NCT05999968 · Eli Lilly and Company
2024-01-12 – 2026-01-21 · Prostatic Neoplasms
What this study did
NCT04627064 · Dana-Farber Cancer Institute
2020-12-31 – 2024-08-04 · Clear Cell Renal Cell Carcinoma
What this study did
NCT04074785 · University of Texas Southwestern Medical Center
2019-12-13 – 2023-10-16 · GBM, Glioblastoma, Brain Tumor, Brain Tumor, Recurrent
What this study did
NCT04049227 · Northwestern University
2019-08-12 – 2023-05-15 · Endometrial Endometrioid Adenocarcinoma
What this study did
NCT02857270 · Eli Lilly and Company
2016-09-29 – 2022-10-24 · Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
What this study did
NCT01394016 · Eli Lilly and Company
2009-12-07 – 2022-04-12 · Advanced Cancer
What this study did
NCT03905889 · Brown University
2019-06-05 – 2022-03-08 · Renal Cell Carcinoma Metastatic
What this study did
NCT04071262 · Eli Lilly and Company
2019-12-20 – 2021-08-30 · Advanced Cancer
What this study did
NCT02688088 · Eli Lilly and Company
2016-03-08 – 2021-01-06 · Neoplasm Metastasis
What this study did
NCT02919696 · Eli Lilly and Company
2017-08-07 – 2019-09-03 · Advanced Cancer, Metastatic Cancer
What this study did
NCT02079636 · Eli Lilly and Company
2014-03-28 – 2019-08-29 · Carcinoma, Non-small Cell Lung
What this study did
NCT02014129 · Eli Lilly and Company
2013-12-18 – 2019-08-21 · Neoplasm Metastasis, Lymphoma
What this study did
NCT02411591 · Eli Lilly and Company
2015-06-04 – 2019-05-28 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
What this study did
NCT02745769 · Eli Lilly and Company
2016-10-21 – 2019-01-22 · Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
What this study did
Phase 4 (9)
Breast Cancer
NCT07599137 · Peking University Cancer Hospital & Institute
2026-05-30 – 2028-02-01 · HR+/HER2- Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06169371 · University of Illinois Chicago
2023-12-28 – 2030-11 · Breast Cancer
What this study did
NCT07490509 · Poitiers University Hospital
2026-09 – 2029-09 · Abemaciclib, Abemaciclib-related Diarrhea, Breast Cancer
What this study did
NCT05362760 · Prof. Wolfgang Janni
2022-04-27 – 2029-04 · Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
What this study did
NCT07487129 · Beni-Suef University
2024-08-25 – 2025-12-20 · Breast Cancer
What this study did
NCT03988114 · Eli Lilly and Company
2019-09-16 – 2023-03-23 · Metastatic Breast Cancer
What this study did
NCT04707196 · Eli Lilly and Company
2021-02-22 – 2023-01-09 · Breast Neoplasms, Neoplasm Metastasis
What this study did
NCT04031885 · Eli Lilly and Company
2019-08-14 – 2020-08-11 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT05691400 · University of Michigan Rogel Cancer Center
2024-03 – 2027-03 · CYP3A4*22
What this study did
Early phase / not applicable (3)
Breast Cancer
NCT06810492 · Hongmei Zheng, PhD
2025-04-01 – 2027-12-01 · Breast Cancer Stage III, Breast Cancer Stage II
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07406594 · University of Vermont Medical Center
2027-10 – 2031-10 · Breast Cancer, HER-2 Positive Breast Cancer
What this study did
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
HR+/HER2- Metastatic Breast Cancer
NCT06585969 · Danish Breast Cancer Cooperative Group
2026-01-01 – 2026-01-01 · Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like
What this study did
Phase 2 (1)
HR+/HER2- Metastatic Breast Cancer
NCT05766410 · National Taiwan University Hospital
2022-09-16 – 2026-09-30 · Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
What this study did
Phase 1/2 (1)
Early phase / not applicable (1)
HR+/HER2- Metastatic Breast Cancer
NCT07706933 · Henan Cancer Hospital
2026-11-01 – 2033-06-30 · Breast Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07174336 · Eli Lilly and Company
2025-12-22 – 2033-05 · Breast Neoplasms, Neoplasm Metastasis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Abemaciclib (Verzenio): this drugApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(92 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Verzenio (Abemaciclib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-11 · NCT07818967 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05305924 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04393285 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
2027 (44)
January 2027 (4)
Phase 1Myelofibrosis Due to and Following Polycythemia VeraRecruiting
Est. primary completion 2027-01 · NCT05714072 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2027-01-01 · NCT03310879 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-10 · NCT06207734 · CT.gov ↗
What to watch
Phase 1/2Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma …Recruiting
Est. primary completion 2027-01-31 · NCT06498648 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1/2Metastatic Renal Cell Carcinoma, Translocation Renal Cell CarcinomaRecruiting
Est. primary completion 2027-02 · NCT06835972 · CT.gov ↗
What to watch
Phase 2GliomaActive not recruiting
Est. primary completion 2027-02 · NCT06413706 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2027-02-25 · NCT06341621 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-03-20 · NCT06594679 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-24 · NCT05548127 · CT.gov ↗
What to watch
Phase 1/2GliomaRecruiting
Est. primary completion 2027-03-31 · NCT06810544 · CT.gov ↗
What to watch
April 2027 (6)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT05696626 · CT.gov ↗
What to watch
Phase 1Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma …Recruiting
Est. primary completion 2027-04-01 · NCT06654037 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT05501704 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-15 · NCT04614194 · CT.gov ↗
What to watch
Phase 2Liver Metastases From Colorectal Cancer (mCRC)Enrolling by invitation
Est. primary completion 2027-04-30 · NCT07441369 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Neoplasms, Child, AdolescentRecruiting
Est. primary completion 2027-05 · NCT05999994 · CT.gov ↗
What to watch
Phase 1Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian CarcinomaRecruiting
Est. primary completion 2027-05-01 · NCT04633239 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-21 · NCT04305834 · CT.gov ↗
What to watch
Phase 1/2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2027-05-31 · NCT05113537 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05095207 · CT.gov ↗
What to watch
Phase 1/2Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT05774899 · CT.gov ↗
What to watch
Phase 2Chondrosarcoma, Osteosarcoma, Soft Tissue SarcomaRecruiting
Est. primary completion 2027-06-01 · NCT04040205 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-07 · NCT05372640 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06188520 · CT.gov ↗
What to watch
July 2027 (5)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT05735080 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT04923542 · CT.gov ↗
What to watch
Phase 2Sarcoma, Dedifferentiated LiposarcomaActive not recruiting
Est. primary completion 2027-07 · NCT02846987 · CT.gov ↗
What to watch
Phase 2Brain TumorActive not recruiting
Est. primary completion 2027-07 · NCT03220646 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05386108 · CT.gov ↗
What to watch
Phase 1Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated LiposarcomaRecruiting
Est. primary completion 2027-08-03 · NCT06025747 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Recurrent Endometrial Cancer, TP53Recruiting
Est. primary completion 2027-09-01 · NCT06366347 · CT.gov ↗
What to watch
Phase 2Malignant Neoplasms of Female Genital OrgansActive not recruiting
Est. primary completion 2027-09-30 · NCT03531645 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT04862663 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12 · NCT06365788 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT04523857 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07935317 · CT.gov ↗
What to watch
Phase 3Advanced Dedifferentiated LiposarcomaActive not recruiting
Est. primary completion 2027-12 · NCT04967521 · CT.gov ↗
What to watch
Phase 4Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07599137 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05608252 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
2028 (25)
January 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01 · NCT05872204 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (4)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
Phase 2GlioblastomaRecruiting
Est. primary completion 2028-02-01 · NCT02977780 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2Kaposi SarcomaRecruiting
Est. primary completion 2028-03-01 · NCT04941274 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
May 2028 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
June 2028 (3)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-06 · NCT04565054 · CT.gov ↗
What to watch
Phase 2Intracranial Meningioma, Recurrent Meningioma, NF2 Gene MutationRecruiting
Est. primary completion 2028-06-01 · NCT02523014 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT05708235 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-07-01 · NCT06062498 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-07-31 · NCT07112053 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-08-01 · NCT03675893 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2MeningiomaRecruiting
Est. primary completion 2028-09 · NCT05940493 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-10-01 · NCT07209449 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-10-31 · NCT07905001 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-11-30 · NCT06678269 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT07292207 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Low Grade Ovarian Serous Adenocarcinoma, Endometrial CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07832227 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colorectal Carcinoma …Active not recruiting
Est. primary completion 2028-12-31 · NCT04616183 · CT.gov ↗
What to watch
Phase 1/2Neurofibromatosis 1Recruiting
Est. primary completion 2028-12-31 · NCT04750928 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05524584 · CT.gov ↗
What to watch
2029 (7)
April 2029 (3)
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT05362760 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT07410559 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-04-30 · NCT07428018 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-06-30 · NCT07605728 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07490509 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
2030 (8)
March 2030 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2030-03-04 · NCT05952557 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-04-30 · NCT07191717 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-10 · NCT04584853 · CT.gov ↗
What to watch
November 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-11 · NCT06169371 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗
What to watch
October 2031 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-10 · NCT07406594 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2034-02-06 · NCT07190443 · CT.gov ↗
What to watch

See the full readout calendar ↗